Research findings
Retatrutide found to be dosed double the labelled amount
Half Year Laboratory Summary Jan–June 2026
Laboratory Analysis of Illicit Market Peptides
Each bar shows how far the measured content sat from the label's claim. The labelled dose is the reference line at zero. Ordered by magnitude of deviation.
{{ r.name }}
{{ r.gloss }}
{{ r.dev }}
{{ r.measured }}
Based on 7 consumer-submitted samples analysed January–June 2026. Small sample size — indicative, not representative. A dose matching its label is accurate, not safe.
Read the Half Year Summary HereBulletins & snapshots
Research Findings
Half-year bulletin · Latest
January–June 2026
Legitimacy outcomes across 7 consumer-submitted samples: compound accuracy, dose deviation, and what people did with their results.
Read the Bulletin →Surveillance snapshot · Cycle 1
Quarterly snapshot 01
The first rolling three-month snapshot: what's circulating in Queensland's IPED market and which formulations matched their labels.
In analysisHalf-year bulletin · Next
July–December 2026
The second bulletin adds within-person change over time via anonymous linking codes — the first longitudinal look at the market.
Coming early 2027